Invivyd, Inc. Files 8-K
Ticker: IVVD · Form: 8-K · Filed: Sep 3, 2024 · CIK: 1832038
| Field | Detail |
|---|---|
| Company | Invivyd, INC. (IVVD) |
| Form Type | 8-K |
| Filed Date | Sep 3, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: sec-filing, corporate-reporting
TL;DR
Invivyd filed a routine 8-K, no major news.
AI Summary
Invivyd, Inc. filed an 8-K on September 3, 2024, reporting other events and financial statements. The company, formerly known as Adagio Therapeutics, Inc., is incorporated in Delaware and headquartered in Waltham, MA. This filing does not appear to contain specific financial transaction details or significant operational updates beyond routine reporting.
Why It Matters
This 8-K filing indicates routine corporate reporting by Invivyd, Inc. to the SEC, which is standard practice for publicly traded companies.
Risk Assessment
Risk Level: low — The filing appears to be a standard corporate disclosure without any immediate material events or financial changes.
Key Players & Entities
- Invivyd, Inc. (company) — Registrant
- Adagio Therapeutics, Inc. (company) — Former Name
- September 3, 2024 (date) — Report Date
- Delaware (jurisdiction) — State of Incorporation
- Waltham, MA (location) — Principal Executive Offices
FAQ
What is the primary purpose of this 8-K filing for Invivyd, Inc.?
The 8-K filing reports 'Other Events' and 'Financial Statements and Exhibits' as of September 3, 2024.
When was Invivyd, Inc. formerly known as?
Invivyd, Inc. was formerly known as Adagio Therapeutics, Inc., with a name change date of November 12, 2020.
Where are Invivyd, Inc.'s principal executive offices located?
Invivyd, Inc.'s principal executive offices are located at 1601 Trapelo Road, Suite 178, Waltham, MA 02451.
What is the state of incorporation for Invivyd, Inc.?
Invivyd, Inc. is incorporated in Delaware.
What is the SEC file number for Invivyd, Inc.?
The SEC file number for Invivyd, Inc. is 001-40703.
Filing Stats: 437 words · 2 min read · ~1 pages · Grade level 10.2 · Accepted 2024-09-03 07:07:00
Key Financial Figures
- $0.0001 — ch registered Common stock, par value $0.0001 per share IVVD The Nasdaq Stock Mar
Filing Documents
- ivvd-20240903.htm (8-K) — 44KB
- ivvd-ex99_1.htm (EX-99.1) — 40KB
- img59752938_0.jpg (GRAPHIC) — 12KB
- 0000950170-24-102552.txt ( ) — 232KB
- ivvd-20240903.xsd (EX-101.SCH) — 31KB
- ivvd-20240903_htm.xml (XML) — 5KB
01
Item 8.01. Other Events. On September 3, 2024, Invivyd, Inc. issued a press release entitled "Invivyd Announces Continued Neutralizing Activity of PEMGARDA (pemivibart) Against Dominant SARS-CoV-2 Variants KP.3.1.1 and LB.1, and Other Variants of Interest." A copy of the press release is filed herewith as Exhibit 99.1 and is incorporated by reference in this Item 8.01.
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release, dated September 3, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. INVIVYD, INC. Date: September 3, 2024 By: /s/ Jill Andersen Jill Andersen Chief Legal Officer and Corporate Secretary